Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

that prevent cell-to-cell transmission of virus down the respiratory tract, potentially reducing the severity of influenza disease; and cell mediated immune responses to M1 may lead to destruction of cells already infected. Further, the vaccine is made in cell culture rather than eggs, which permits an exact genetic match to the flu strains causing illness since there is no requirement for adapting the vaccine to grow in eggs.

"We are pleased to complete enrollment so quickly of our seasonal influenza vaccine Phase IIa trial", said Dr. Rahul Singhvi, President and CEO of Novavax. "The completion of enrollment for this critical clinical trial within a week of its initiation should enable us to release top line data from this study in the fourth quarter of this year. I congratulate our team on this accomplishment and for advancing two novel influenza vaccines into Phase II development this year."

Novavax's novel manufacturing approach

Novavax's manufacturing process makes it possible to rapidly produce a vaccine that contains strains that are an exact genetic match to the strains circulating in the community causing influenza disease. Novavax's influenza VLPs are produced through recombinant technology in insect cell culture, utilizing a manufacturing process that will consist entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than those of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, a matched vaccine for the first seasonal influenza clinical trial was manufactured within 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, ... government, announced in a paper published this week in the scientific journal Viruses ... the diagnostic techniques currently used to detect the Ebola virus. Noblis worked with ...
(Date:6/30/2015)...  Custom Computer Specialists, Inc. ("Custom"), a leading healthcare ... sponsors of the Primary Care Development Corporation,s ("PCDC") Corporate ... their support of PCDC,s mission to expand access to ... founding in 1993, PCDC has been a key force ... financed over 100 completed primary care projects, valued at ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys ... a revolutionary new archwire that allows orthodontists to simultaneously apply different forces to ... efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... 2011 The Association for Career and ... Readiness Through Career and Technical Student Organizations." The ... technical student organizations (CTSOs) strengthen their career readiness ... development, academic and career development, professional development and ...
... Reportlinker.com announces that a new market research report ... Biobanking: Technologies and Global Markets ... THIS REPORT CONTAINS ... types: Population, Disease, and Private Sector ...
... 2011 ,   Amsterdam ... human gene therapy, today announced the appointment of,Dr. Carlos ... AMT more than 25 years of pharmaceutical industry experience,most ... approvals at the European Medicines Agency (EMA),and U.S. Food ...
Cached Biology Technology:ACTE Releases Paper on How Career, Technical Student Organizations Expand Career Readiness for Students 2ACTE Releases Paper on How Career, Technical Student Organizations Expand Career Readiness for Students 3Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 2Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 3
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... Release February 8, 2011 - (Toronto) A new ... has found evidence suggesting that a variation of a specific ... which accounts for over 90% of Alzheimer,s cases. This innovative ... may be at risk for developing late-onset Alzheimer,s disease long ...
... (February 7, 2011) Tufts University today announced the ... website/HUB: www.tuftspharmapartners.org The Institute ... and manage a diverse portfolio of drug discovery and ... and is managed by Tufts University School of Medicine ...
... BATON ROUGE Fish bait: it,s messy, smelly and ... one day, but with expensive and more permanent lures, you ... breaks. Soft baits, those gummy pieces of brightly colored plastic ... as visual cues for fish. LSU Professor John Caprio and ...
Cached Biology News:Combining brain imaging, genetic analysis may help identify people at early risk of Alzheimer's 2Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB 2Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB 3LSU biologist, chemical engineer partner with industry to develop best soft lure available 2LSU biologist, chemical engineer partner with industry to develop best soft lure available 3LSU biologist, chemical engineer partner with industry to develop best soft lure available 4
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
SHEEP ANTI HUMAN ESTRONE...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
... the materials necessary for the isolation and preparation ... analysis. Kit Components: ... bottle containing 220 mL of buffered ammonium chloride. ... (Catalog No. 5113) One bottle containing 220 mL ...
Biology Products: